Michael Murray, MD
Otolaryngology · San Jose, CANPI 1750475828
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Med-el Corporation accounts for 88.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $6,476 and has fallen 98.6% since, to $90 in 2025.
Across 33 payments — averaging $220.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Med-el Corporation$6K
- Cochlear Americas$420
- Advanced Bionics, LLC$258
- Smith+Nephew$76
- Intersect ENT, Inc.$24
- Sanofi$22
- plus $25 from 2 others
Across 4 payments — averaging $281.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$1K
What the payments were for
- Speaking & faculty fees$3,00041%
- Travel & lodging$3,04142%
- Food & beverage$1,24017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Med-el Corporation | 14 | $6,457 |
| Cochlear Americas | 7 | $420 |
| Advanced Bionics, LLC | 6 | $258 |
| Smith+Nephew | 2 | $76 |
| Intersect ENT, Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Stryker | 1 | $12 |
| Agiliti Surgical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,281 in reported general payments places this provider in the 85th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 57 | $2,265 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $1,326 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $522 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 32 | $520 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $270 |
| Montelukast Sodium | 19 | $268 |
| Ondansetron Hcl | 42 | $131 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in San Jose
- Brian WeeksSan Diego$924K
- Randall OwRoseville$613K
- Amir MoradiVista$389K
- Keith BlackwellLos Angeles$349K
- Kalpna DurairajSun Valley$348K
- Todd MillerNewport Beach$259K
- Jeffrey SuhLos Angeles$223K
- Dennis TangLos Angeles$209K
- Jeffrey FeinfieldThousand Oaks$160K
- Jonathan SykesGranite Bay$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.